Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Operations (2023 - 2025)

Kura Oncology (KURA) has disclosed Cash from Operations for 3 consecutive years, with 117273000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 56.43% to 117273000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 64058000.0, a 147.69% decrease, with the full-year FY2025 number at 64058000.0, down 147.69% from a year prior.
  • Cash from Operations was 117273000.0 for Q4 2025 at Kura Oncology, up from 80627000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 269131000.0 in Q4 2024 to a low of 80627000.0 in Q3 2025.
  • A 3-year average of 4547083.33 and a median of 35090000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 884.46% in 2024, then crashed 85.61% in 2025.
  • Kura Oncology's Cash from Operations stood at 34308000.0 in 2023, then surged by 884.46% to 269131000.0 in 2024, then plummeted by 56.43% to 117273000.0 in 2025.
  • Per Business Quant, the three most recent readings for KURA's Cash from Operations are 117273000.0 (Q4 2025), 80627000.0 (Q3 2025), and 28777000.0 (Q2 2025).